HIV cell therapy biotech Addimmune to go public via SPAC merger; WHO names new Covid-19 'variant of interest'
Addimmune, a biotech that is working on a cell therapy for HIV, announced Wednesday that it plans to merge with 10X …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
